BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells $7,804,944.00 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 41,760 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $186.90, for a total transaction of $7,804,944.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, November 26th, Xiaodong Wang sold 40,468 shares of BeiGene stock. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80.

BeiGene Trading Down 0.5 %

BeiGene stock opened at $179.35 on Friday. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $248.16. The firm’s 50-day moving average is $207.23 and its 200-day moving average is $186.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The company has a market cap of $17.47 billion, a P/E ratio of -21.77 and a beta of 0.57.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue was up 28.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. On average, equities analysts expect that BeiGene, Ltd. will post -5.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BGNE. TD Cowen lifted their target price on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. StockNews.com lowered BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities started coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.69.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its stake in BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after buying an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in BeiGene in the 3rd quarter valued at about $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BeiGene during the 3rd quarter valued at about $67,000. SG Americas Securities LLC bought a new position in BeiGene in the 3rd quarter worth about $105,000. Finally, PFG Investments LLC bought a new position in BeiGene in the 3rd quarter worth about $210,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.